Statements (19)
Predicate | Object |
---|---|
gptkbp:instanceOf |
small molecule
investigational drug |
gptkbp:administeredBy |
oral route
|
gptkbp:CASNumber |
1693758-51-8
|
gptkbp:chemicalFormula |
C24H24N6O2
|
gptkbp:clinicalTrialPhase |
Phase 1/1b
|
gptkbp:combinationTherapy |
immune checkpoint inhibitors
|
gptkbp:developedBy |
gptkb:Infinity_Pharmaceuticals
|
gptkbp:effect |
modulates tumor microenvironment
reduces immunosuppression |
https://www.w3.org/2000/01/rdf-schema#label |
IPI-549
|
gptkbp:intendedUse |
immunotherapy
|
gptkbp:mechanismOfAction |
PI3K-gamma inhibition
|
gptkbp:studiedBy |
solid tumors
advanced cancers |
gptkbp:synonym |
gptkb:PI3K-gamma_inhibitor_IPI-549
|
gptkbp:target |
gptkb:PI3K-gamma
|
gptkbp:bfsParent |
gptkb:PIK3CG
|
gptkbp:bfsLayer |
5
|